The incidence of PAC is relatively infrequent among pregnant women. However, it has gradually increased in recent years, becoming a challenging area for clinicians that should take into account in the same way maternal benefits and fetal potential risks correlated to the antineoplastic treatment. None of the antineoplastic drugs is completely risk-free during the pregnancy, the timing of exposure and transplacental transfer properties influence the toxicity of the fetus. Despite the lack of guidelines about the management of PAC, several studies have described the use and the potential fetal and neonatal adverse events of antineoplastic drugs during pregnancy. We provide a review of the available literature about the transplacental passage and fetal effects of chemotherapy and targeted agents, to guide the clinicians in the most appropriate choices for the management of PAC.

Triarico, S., Rivetti, S., Capozza, M. A., Romano, A., Maurizi, P., Mastrangelo, S., Attina, G., Ruggiero, A., Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy, <<CANCERS>>, 2022; 14 (13): N/A-N/A. [doi:10.3390/cancers14133103] [https://hdl.handle.net/10807/223515]

Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy

Rivetti, Serena;Maurizi, Palma;Mastrangelo, Stefano;Ruggiero, Antonio
2022

Abstract

The incidence of PAC is relatively infrequent among pregnant women. However, it has gradually increased in recent years, becoming a challenging area for clinicians that should take into account in the same way maternal benefits and fetal potential risks correlated to the antineoplastic treatment. None of the antineoplastic drugs is completely risk-free during the pregnancy, the timing of exposure and transplacental transfer properties influence the toxicity of the fetus. Despite the lack of guidelines about the management of PAC, several studies have described the use and the potential fetal and neonatal adverse events of antineoplastic drugs during pregnancy. We provide a review of the available literature about the transplacental passage and fetal effects of chemotherapy and targeted agents, to guide the clinicians in the most appropriate choices for the management of PAC.
Inglese
Triarico, S., Rivetti, S., Capozza, M. A., Romano, A., Maurizi, P., Mastrangelo, S., Attina, G., Ruggiero, A., Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy, <<CANCERS>>, 2022; 14 (13): N/A-N/A. [doi:10.3390/cancers14133103] [https://hdl.handle.net/10807/223515]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/223515
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact